PARABILIS MEDICINES, INC. COMMON STOCK

NASDAQ: PBLS (Parabilis Medicines, Inc.)

Kemas kini terakhir: 6 jam lalu

27.44

-0.18 (-0.67%)

Penutupan Terdahulu 27.63
Jumlah Dagangan 1,246,548
Purata Dagangan (3B) 975,548
Modal Pasaran 3,437,074,688
Harga / Jualan (P/S) 716.26
Harga / Buku (P/B) 3.38
Julat 52 Minggu
22.66 (-17%) — 42.49 (54%)
Tarikh Pendapatan 12 Nov 2026
Margin Operasi (TTM) -8,509.77%
EPS Cair (TTM) -3.62
Jumlah Hutang/Ekuiti (D/E MRQ) 4.16%
Nisbah Semasa (MRQ) 12.88
Aliran Tunai Operasi (OCF TTM) -120.83 M

AISkor Stockmoo

0.8
Hutang rendah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Pulangan atas Modal info NA
Trend Perolehan info NA
Nilai Pegangan info NA
Premium Risiko info NA
Penilaian Pasaran info NA
Daripada analisis teknikal AI kami terhadap carta. info NA
Kekuatan Aliran info NA
Persediaan Teknikal info NA
Corak Lilin info NA
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Berita terkini kebanyakannya positif. info
Sentimen Pegangan info NA
Institusi bersih +21.81% daripada saham dalam pemfailan 13F terkini: 86 pemegang menambah, 20 mengurang (suku berakhir 30 Sep 2026). info
Kedudukan jual singkat +100.3% dari 31 Aug hingga 30 Oct 2026, 8.3 hari untuk tutup (FINRA). info
Aktiviti Orang Dalam info NA
Persekitaran pasaran berhati-hati. info
Sektor ketinggalan berbanding pasaran.
Tonggak-tonggak sependapat, jadi skor diperkukuh.
Di bawah garis aliran jangka sederhana. info
Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info
Momentum jangka pendek semakin lemah. info
Harga hampir dengan paras sokongan. info
Skor Akhir 0.77
Tunjuk semua

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menaik
Biotechnology (Global) Bercampur Menaik
Stok Parabilis Medicines, Inc. - -

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B Skor
PBLS 3 B - - 3.38 0.8
LEGN 3 B - - 2.59 -1.6
PVLA 2 B - - 10.82 0.9
MAZE 2 B - - 4.13 0.9
IMCR 1 B - - 3.24 -0.2
GPCR 1 B - - 1.01 -0.8

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Orang Dalam 6.93%
% Dimiliki oleh Institusi 89.48%

Pemilikan

Nama Tarikh Syer Dipegang
Venbio Partners Llc 30 Sep 2026 5,266,697
Regeneron Pharmaceuticals, Inc. 30 Sep 2026 4,166,666

Tiada data dalam julat masa ini.

Institusi

Pemilikan institusi: 90.89%

Kedudukan Pemegang Saham
Bertambah 86 16,079,357
Berkurang 20 344,014
Baharu 60 11,492,551
Dijual habis 10 178,319

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 11,052,337 8.3
15 Oct 2026 9,250,099 9.5
30 Sep 2026 8,261,483 4.8
15 Sep 2026 6,092,212 13.3
31 Aug 2026 5,517,704 14.2
14 Aug 2026 5,257,000 15.7

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

2 Positif 0 Negatif 1 Neutral
Tarikh Jenis Butiran
17 Nov 2026 Yahoo Finance Does Parabilis Medicines (PBLS) Have the Potential to Rally 44.11% as Wall Street Analysts Expect?
The mean of analysts' price targets for Parabilis Medicines (PBLS) points to a 44.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
12 Nov 2026 Yahoo Finance Parabilis Medicines: Q3 Earnings Snapshot
(AP) — Parabilis Medicines Inc. (PBLS) on Thursday reported a loss of $44…
12 Nov 2026 Yahoo Finance Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates
Presented updated Phase 1/2 data at ESMO Congress 2026 demonstrating a 72.2% objective response rate at the 32-week landmark and a favorable safety and tolerability profile for zolucatetide in desmoid tumors Reached alignment with the U.S. FDA on dose, regimen and trial design for upcoming PEDESTAL…
03 Nov 2026 Yahoo Finance Parabilis Medicines to Participate in Upcoming November Investor Conferences
CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced that Mathai Mammen…
24 Oct 2026 Yahoo Finance Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027
Parabilis Medicines (NASDAQ:PBLS) presented updated interim phase I/II data for investigational beta-catenin/TCF inhibitor zolucatetide in desmoid tumors at the European Society for Medical Oncology Congress in Madrid, reporting tumor responses, disease control and an FDA-aligned plan for a registra…
24 Oct 2026 Yahoo Finance Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week landmarkDisease control rate of 100% across all response-evaluable patients receiving a starting dose of ≥450 mg, with no disease progression and no treatment discontinuations due to…
20 Oct 2026 Yahoo Finance Parabilis Medicines (PBLS) Stock May Trade At A Premium Despite Fresh Zolucatetide Trial Updates
Parabilis Medicines shares have retreated sharply in recent weeks, and that pullback puts fresh focus on what the current price implies relative to the drug developer’s book value. With sentiment swinging around new clinical updates, the key issue is how much of the balance sheet and pipeline risk…
20 Oct 2026 Yahoo Finance Parabilis Medicines (PBLS) Could Be 39% Undervalued As Zolucatetide Trial Expands
Parabilis Medicines (PBLS) has drawn fresh attention after announcing a new dose ranging cohort for its lead drug candidate, zolucatetide, in familial adenomatous polyposis, expanding an ongoing Phase 1/2 trial. The fresh zolucatetide cohort lands in a volatile stretch for Parabilis Medicines, with…
20 Oct 2026 Yahoo Finance What Does Parabilis Medicines (PBLS) Expanding Zolucatetide Into FAP Mean?
Parabilis Medicines (NasdaqGS:PBLS) reported updated Phase 1/2 clinical data for lead candidate zolucatetide in patients with desmoid tumors. The biotechnology company plans to present the new zolucatetide desmoid tumor data at a major oncology congress in 2026. Management has expanded zolucatetide…
19 Oct 2026 Yahoo Finance Parabilis Soars 13% on Upcoming ESMO Data for “First-in-Class” Desmoid Tumor Drug
Key TakeawaysParabilis Medicines shares rose 13% today after the company said it will present updated zolucatetide data in desmoid tumors at ESMO on Saturday, Oct. 24…
19 Oct 2026 Yahoo Finance Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026
Oral presentation will include updated data from the ongoing Phase 1/2 trial, with dose optimization arm designed to inform dose and regimen selection for Phase 3 registrational trial in desmoid tumors Company to host webcast on Saturday, October 24, 2026, at 6 p.m. CEST / 12 p.m. EDT CAMBRIDGE…
14 Oct 2026 Yahoo Finance Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors Zolucatetide directly inhibits β-catenin:TCF, targeting the APC-mutation biology that drives precancerous adenomatous polyp formation in…
13 Oct 2026 Yahoo Finance Phanes Therapeutics to participate in Longwood Healthcare Leaders Boston CEO, November 2-3, 2026
Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), announced that Ming Wang (CEO) will participate in Boston CEO, November 2-3, 2026, at the Mandarin Oriental Hotel in Boston, MA. He will speak on a…
28 Sep 2026 Yahoo Finance Sixty Degree Capital Extends Its Track Record as Five Portfolio Companies Enter the Public Markets in 2026
Sixty Degree Capital ("SDC"), a global, multi-stage venture capital firm investing across technology and healthcare, continued its strong portfolio momentum in 2026. Building on the firm's history of successful exits, five SDC portfolio companies have completed initial public offerings in 2026…
23 Sep 2026 Yahoo Finance MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Directors. Mr. Sebulsky is a veteran healthcare portfolio manager and…
01 Sep 2026 Yahoo Finance Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced its Chairman, President…
25 Aug 2026 Yahoo Finance Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the appointment of Craig…
24 Aug 2026 Yahoo Finance Young startups miss out on biotech venture funding rebound, MassBio says
A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in opposite directions, as funding slows for young companies with the “riskiest science.”
Papar semua

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Risiko / Ganjaran
TP1:
TP2:

Kerugian hingga SL berbanding keuntungan hingga setiap sasaran, dari EP. Nisbah 2 atau lebih biasanya dicari.

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda